Patent intelligence · US
US 8133894
N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones
N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones
Patent details — US 8133894
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 13, 2012
- Expiration
- Mar 8, 2032
- Applicant
- Akebia Therapeutics, Inc.
- Claims
- 15
- CPC classes
- A61P, A61P31/00, A61P31/04
Quick answer
US 8133894 (N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones) is held by Akebia Therapeutics, Inc.. Status: granted. Granted Mar 13, 2012. Expires Mar 8, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Akebia Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61P, A61P31/00, A61P31/04
More from Akebia Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419877
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 11883386
Prolyl hydroxylase inhibitors and methods of use
granted -
US 11857543
Compositions and methods for treating anemia
granted -
US 11844756
Compositions and methods for treating anemia
granted -
US 11690836
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 11524939
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
granted -
US 11426393
Prolyl hydroxylase inhibitors and methods of use
granted -
US 11324734
Compositions and methods for treating anemia
granted
Frequently asked questions
What is US patent 8133894?
US 8133894 (N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones) is held by Akebia Therapeutics, Inc.. Status: granted. Granted Mar 13, 2012. Expires Mar 8, 2032 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8133894?
Akebia Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 8133894 expire?
Our index shows an expiration date of Mar 8, 2032 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.